Loading stock data…
YDES
$2.42+0.07 (+2.98%)
After Hours$2.46+0.04 (+1.65%)· Last close Jun 29
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
YD Bio Ltd in the Healthcare sector is trading at $2.42 with a market capitalization of $197M. The stock is currently near its 52-week low of $2.14, remaining 75.7% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q4 2025 | Q2 2025 |
|---|---|---|
| Total Revenue | — | — |
| Gross Profit | — | — |
| Operating Income | — | — |
| Net Income | — | — |
Peer Comparison
JNJUNHPFE
Fundamentals
YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Tai...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$196.91M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-
Volume
Today's trading volume
17,062
Recent News
Breeze Holdings Acquisition (YDES) Rises 31% Over the Past Month
In recent events, YD Bio Limited's addition to the NASDAQ Composite Index has elevated the company's market standing, while Breeze Holdings Acquisition (YDES) has seen a 31% price rise over the past month. This surge coincides with significant developments, including a business combination with Taiwan-based YD Biopharma, signaling a move to strengthen their presence in the biopharmaceutical industry. These corporate actions place the company's recent performance against the backdrop of a...
Top Midday Gainers
Professional Diversity Network (IPDN) said Friday it signed a non-binding memorandum of understandin